Device Debut: STS' Stent For Chronic Sinusitis Gets US Go-Ahead
Executive Summary
The Israeli portfolio company of The Trendlines Group announced that US FDA 510(k)-cleared its composite removable sinus stent system based on results of a 30-patient trial.